265 related articles for article (PubMed ID: 32713353)
1. Glucagon-like peptide-1 response to whey protein is less diminished by dipeptidyl peptidase-4 in comparison with responses to dextrin, a lipid and casein in rats.
Shimizu Y; Hara H; Hira T
Br J Nutr; 2021 Feb; 125(4):398-407. PubMed ID: 32713353
[TBL] [Abstract][Full Text] [Related]
2. Daily supplementation of dietary protein improves the metabolic effects of GLP-1-based pharmacotherapy in lean and obese rats.
Mietlicki-Baase EG; Koch-Laskowski K; McGrath LE; Krawczyk J; Pham T; Lhamo R; Reiner DJ; Hayes MR
Physiol Behav; 2017 Aug; 177():122-128. PubMed ID: 28433470
[TBL] [Abstract][Full Text] [Related]
3. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.
Sternkopf M; Nagy M; Baaten CCFMJ; Kuijpers MJE; Tullemans BME; Wirth J; Theelen W; Mastenbroek TG; Lehrke M; Winnerling B; Baerts L; Marx N; De Meester I; Döring Y; Cosemans JMEM; Daiber A; Steven S; Jankowski J; Heemskerk JWM; Noels H
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e65-e77. PubMed ID: 31893947
[TBL] [Abstract][Full Text] [Related]
4. Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed rats.
Liu X; Murali SG; Holst JJ; Ney DM
Am J Physiol Regul Integr Comp Physiol; 2009 Nov; 297(5):R1554-62. PubMed ID: 19776251
[TBL] [Abstract][Full Text] [Related]
5. Intraduodenal milk protein concentrate augments the glycemic and food intake suppressive effects of DPP-IV inhibition.
Olivos DR; McGrath LE; Turner CA; Montaubin O; Mietlicki-Baase EG; Hayes MR
Am J Physiol Regul Integr Comp Physiol; 2014 Feb; 306(3):R157-63. PubMed ID: 24352410
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY.
Guida C; McCulloch LJ; Godazgar M; Stephen SD; Baker C; Basco D; Dong J; Chen D; Clark A; Ramracheya RD
Diabetes Obes Metab; 2018 Mar; 20(3):571-581. PubMed ID: 28892258
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
Abouelkheir M; El-Metwally TH
Eur J Pharmacol; 2019 Nov; 862():172638. PubMed ID: 31491403
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
9. Differential responses of the incretin hormones GIP and GLP-1 to increasing doses of dietary carbohydrate but not dietary protein in lean rats.
Yoder SM; Yang Q; Kindel TL; Tso P
Am J Physiol Gastrointest Liver Physiol; 2010 Aug; 299(2):G476-85. PubMed ID: 20522638
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
[TBL] [Abstract][Full Text] [Related]
11. Hindbrain DPP-IV inhibition improves glycemic control and promotes negative energy balance.
Mietlicki-Baase EG; McGrath LE; Koch-Laskowski K; Krawczyk J; Pham T; Lhamo R; Reiner DJ; Hayes MR
Physiol Behav; 2017 May; 173():9-14. PubMed ID: 28119159
[TBL] [Abstract][Full Text] [Related]
12. The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation.
Furuta S; Goto M; Tamura M; Yamashita S; Nakaya K; Furuta Y
Drug Res (Stuttg); 2014 Mar; 64(3):130-5. PubMed ID: 23965798
[TBL] [Abstract][Full Text] [Related]
13. Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model.
Al-Awar A; Almási N; Szabó R; Takacs I; Murlasits Z; Szűcs G; Török S; Pósa A; Varga C; Kupai K
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340421
[TBL] [Abstract][Full Text] [Related]
14. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Moritoh Y; Takeuchi K; Hazama M
J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
[TBL] [Abstract][Full Text] [Related]
15. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice.
Smits MM; Galsgaard KD; Jepsen SL; Albrechtsen NW; Hartmann B; Holst JJ
Diabetes; 2024 May; 73(5):671-681. PubMed ID: 38295385
[TBL] [Abstract][Full Text] [Related]
17. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
19. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
20. Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
Andersen ES; Lund A; Bagger JI; Andreasen C; Grøndahl MF; Deacon CF; Hartmann B; Holst JJ; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2018 Aug; 20(8):1937-1943. PubMed ID: 29654643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
